Coronary Artery Disease Clinical Trial
— CIBELESOfficial title:
Randomized Comparison Between Sirolimus-eluting and Everolimus-eluting Coronary Stents in Chronic Coronary Occlusions
Verified date | June 2012 |
Source | Spanish Society of Cardiology |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ministry of Health |
Study type | Interventional |
Chronic total coronary occlusions (CTO) have an especially high risk of angiographic
restenosis, and need for new revascularization procedures. Drug-eluting coronary stents
(DES) have demonstrated to significantly reduce the risk of restenosis and new
revascularization procedures in comparison with bare-metal stents.
Most data on the efficacy of DES come from the sirolimus-eluting coronary stent Cypher
(Cordis corp.), and paclitaxel-eluting coronary stent Taxus (Boston Sci.), and the Cypher
stent is the only DES that has been randomly tested in CTO. Among second-generation DES,
everolimus-eluting stent (EES) has shown excellent angiographic and clinical results, but
this DES has not been studied in unfavourable scenario (such as CTO).
The aim of the CIBELES trial is to demonstrate the hypothesis that EES are equally effective
in comparison with sirolimus-eluting stents in the treatment of CTO, in terms of
angiographic efficacy considered as in-stent late lumen loss.
Status | Completed |
Enrollment | 207 |
Est. completion date | |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients = 18 year-old. - A total occlusion (TIMI 0-1) with an estimated time of occlusion > 2 weeks. - Symptomatic or silent ischaemia, or viable myocardium. - The occlusion is suitable for percutaneous coronary intervention. - The guidewire has crossed the occlusion, and the occlusion has been dilated with balloon or other device. Exclusion Criteria: - Acute myocardial infarction in the myocardial area supplied by the target vessel within 2 weeks before the inclusion in the study. - The lesion can not be crossed with the guidewire and balloon angioplasty. - The vessel has been previously treated percutaneously. - The lesion is not suitable for a 2.25-3.5 coronary stent implantation. - The patient is not willing to undergo an angiographic follow-up. - The patient has contraindications for prolonged double (aspirin plus clopidogrel) anti-platelet therapy (e.g. allergy to aspirin, need for chronic oral anti-coagulation, or scheduled surgical intervention within 12 months. - Pregnancy or absence of pregnancy test in women of childbearing age. - Chronic renal failure (creatinine plasmatic values > 3.0 mg/dl). - Plasmatic platelet count < 100.000 mm-3 or > 700.000 mm-3. - The patient has a severe non-cardiac disease that limits his/her life expectancy to < 1 year. - The patient is currently included in other randomized trial. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Raul Moreno |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | In-stent late lumen loss at 9-month angiographic follow-up | 9 months | No | |
Secondary | Angiographic: rate of binary angiographic restenosis, rate of vessel re-occlusion, and in-segment late loss, at 9 months | 9 and 12 months | Yes | |
Secondary | Clinical: death, myocardial infarction, new revascularization, and angina status at 1 year. | 9 and 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |